Form 4: Lantheus Holdings CEO Brian Markison Reports Acquisition and Disposal of Shares

CEO Brian Markison reports changes in beneficial ownership of Lantheus Holdings stock, including acquisition of restricted stock units and disposal of common stock.

Summary

• On March 1, 2024, Brian Markison, CEO of Lantheus Holdings, reported acquiring 131,496 shares of common stock and disposing of 152,826 shares.
• The acquisition includes 65,748 restricted stock units vesting over three years and 65,748 performance-based restricted stock units (PSUs) that cliff vest after a three-year performance period.
• The PSUs' ultimate award size can range from 0% to 200% of the target based on performance.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock transactions. The acquisition of shares is generally positive, but the disposal could raise minor concerns.

Positives

• The acquisition of restricted stock units and PSUs aligns the CEO's interests with the long-term performance of the company.

Negatives

• The disposal of 152,826 shares could be interpreted negatively by some investors, although it may be part of a pre-planned strategy.

Risks

• The ultimate value of the PSUs is dependent on the company's performance over the next three years, introducing uncertainty.

Future Outlook

The vesting of restricted stock units and PSUs over the next three years suggests a focus on long-term performance and retention of the CEO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing is typical for executives receiving stock-based compensation.

Comparison to Industry Standards

• Stock-based compensation is a common practice among publicly traded companies to align executive incentives with shareholder value.
• The vesting schedules and performance-based components are also standard features of executive compensation packages.
• Comparing Lantheus Holdings' executive compensation structure with peers in the pharmaceutical or medical imaging industry would provide further context.

Stakeholder Impact

• Shareholders may be interested in the CEO's stock transactions as an indicator of confidence in the company's future prospects.

Key Dates